{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:11:44Z","timestamp":1791231104222,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"am","delay-in-days":294,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA129036"],"award-info":[{"award-number":["CA129036"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA179015"],"award-info":[{"award-number":["CA179015"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.canlet.2018.05.009","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T23:33:43Z","timestamp":1525736023000},"page":"47-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":192,"special_numbering":"C","title":["Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN\u03b3 secretion"],"prefix":"10.1016","volume":"430","author":[{"given":"Bharat K.R.","family":"Chaganty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songbo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0923-2989","authenticated-orcid":false,"given":"Anneliese","family":"Gest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Calin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis M.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7485-8179","authenticated-orcid":false,"given":"Zhen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2018.05.009_bib1","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMe058196","article-title":"Trastuzumab in the treatment of breast cancer","volume":"353","author":"Hortobagyi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2018.05.009_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2013mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2018.05.009_bib3","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2018.05.009_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13046-016-0380-5","article-title":"First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?","volume":"35","author":"Fabi","year":"2016","journal-title":"J. Exp. Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2018.05.009_bib5","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3389\/fimmu.2017.01544","article-title":"Interplay between natural killer cells and anti-HER2 antibodies: perspectives for breast cancer immunotherapy","volume":"8","author":"Muntasell","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2018.05.009_bib6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ccr.2010.10.025","article-title":"Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation","volume":"18","author":"Liang","year":"2010","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2018.05.009_bib7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ccr.2010.06.014","article-title":"The therapeutic effect of anti-HER2\/neu antibody depends on both innate and adaptive immunity","volume":"18","author":"Park","year":"2010","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2018.05.009_bib8","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1158\/1078-0432.CCR-12-2522","article-title":"Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells","volume":"19","author":"Mortenson","year":"2013","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2018.05.009_bib9","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1073\/pnas.1016569108","article-title":"Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy","volume":"108","author":"Stagg","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.canlet.2018.05.009_bib10","doi-asserted-by":"crossref","DOI":"10.4161\/onci.24720","article-title":"Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy","volume":"2","author":"Loi","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2018.05.009_bib11","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2217\/imt.14.60","article-title":"Investigating the positive relationship between tumor-infiltrating lymphocytes and trastuzumab therapy","volume":"6","author":"Savas","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.canlet.2018.05.009_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1479-5876-6-25","article-title":"Correlation between NK function and response to trastuzumab in metastatic breast cancer patients","volume":"6","author":"Beano","year":"2008","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2018.05.009_bib13","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/bjc.2011.261","article-title":"T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival","volume":"105","author":"Ladoire","year":"2011","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2018.05.009_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1100790","article-title":"Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNgamma secretion","volume":"5","author":"Chaganty","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2018.05.009_bib15","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2018.05.009_bib16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tips.2015.06.005","article-title":"New immunotherapies targeting the PD-1 pathway","volume":"36","author":"Chinai","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.canlet.2018.05.009_bib17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2018.05.009_bib18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.it.2013.07.003","article-title":"B7 family checkpoint regulators in immune regulation and disease","volume":"34","author":"Ceeraz","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2018.05.009_bib19","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2018.05.009_bib20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2018.05.009_bib21","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2018.05.009_bib22","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.4049\/jimmunol.170.7.3637","article-title":"B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy","volume":"170","author":"Selenko-Gebauer","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2018.05.009_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.canlet.2017.08.006","article-title":"PD-1\/PD-L1 and immunotherapy for pancreatic cancer","volume":"407","author":"Feng","year":"2017","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2018.05.009_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.canlet.2017.06.033","article-title":"PD-1\/PD-L1 checkpoint blockades in non-small cell lung cancer: new development and challenges","volume":"405","author":"Meng","year":"2017","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2018.05.009_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.canlet.2017.07.029","article-title":"PD-1\/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer","volume":"406","author":"Shi","year":"2017","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2018.05.009_bib26","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2018.05.009_bib27","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/ni.2392","article-title":"Immunology beats cancer: a blueprint for successful translation","volume":"13","author":"Pardoll","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2018.05.009_bib28","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","article-title":"Expression of programmed death 1 ligands by murine T cells and APC","volume":"169","author":"Yamazaki","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2018.05.009_bib29","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.febslet.2005.12.093","article-title":"Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274)","volume":"580","author":"Lee","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.canlet.2018.05.009_bib30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.oraloncology.2014.11.014","article-title":"Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma","volume":"51","author":"Ritprajak","year":"2015","journal-title":"Oral Oncol."},{"key":"10.1016\/j.canlet.2018.05.009_bib31","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Canc. Discov."},{"key":"10.1016\/j.canlet.2018.05.009_bib32","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1158\/1078-0432.CCR-13-2797","article-title":"Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma","volume":"20","author":"Atefi","year":"2014","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2018.05.009_bib33","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1078-0432.CCR-15-1125","article-title":"RAS\/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1\/PD-L1 immune checkpoint inhibitors","volume":"22","author":"Loi","year":"2016","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2018.05.009_bib34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2018.05.009_bib35","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/onc.2008.384","article-title":"PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer","volume":"28","author":"Crane","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2018.05.009_bib36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2018.05.009_bib37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2018.05.009_bib38","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2018.05.009_bib39","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2018.05.009_bib40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","article-title":"Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?","volume":"94","author":"Arnould","year":"2006","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2018.05.009_bib41","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1535-7163.MCT-06-0766","article-title":"Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance","volume":"6","author":"Barok","year":"2007","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2018.05.009_bib42","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","article-title":"NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2018.05.009_bib43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00262-011-1090-7","article-title":"Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment","volume":"61","author":"Wang","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2018.05.009_bib44","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.canlet.2013.02.054","article-title":"A novel role of EMMPRIN\/CD147 in transformation of quiescent fibroblasts to cancer-associated fibroblasts by breast cancer cells","volume":"335","author":"Xu","year":"2013","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2018.05.009_bib45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.canlet.2016.10.033","article-title":"CRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation","volume":"385","author":"Wang","year":"2017","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2018.05.009_bib46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2016.05.026","article-title":"Disulfiram targets cancer stem-like properties and the HER2\/Akt signaling pathway in HER2-positive breast cancer","volume":"379","author":"Kim","year":"2016","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2018.05.009_bib47","article-title":"Expansion, purification, and functional assessment of human peripheral blood NK cells","volume":"48","author":"Somanchi","year":"2011","journal-title":"JoVE"},{"key":"10.1016\/j.canlet.2018.05.009_bib48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.canlet.2016.01.009","article-title":"Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism","volume":"373","author":"Ai","year":"2016","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2018.05.009_bib49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.canlet.2016.07.020","article-title":"ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis","volume":"381","author":"Lu","year":"2016","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2018.05.009_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.canlet.2017.08.012","article-title":"AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis","volume":"408","author":"Tao","year":"2017","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2018.05.009_bib51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2016.09.020","article-title":"Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab","volume":"384","author":"Luo","year":"2017","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2018.05.009_bib52","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.4049\/jimmunol.1200356","article-title":"Crosstalk between human IgG isotypes and murine effector cells","volume":"189","author":"Overdijk","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2018.05.009_bib53","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/intimm\/13.12.1551","article-title":"Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies","volume":"13","author":"Ober","year":"2001","journal-title":"Int. Immunol."},{"key":"10.1016\/j.canlet.2018.05.009_bib54","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","article-title":"Affinity of human IgG subclasses to mouse Fc gamma receptors","volume":"9","author":"Dekkers","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.canlet.2018.05.009_bib55","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1167\/iovs.07-1175","article-title":"Interaction between bevacizumab and murine VEGF-A: a reassessment","volume":"49","author":"Yu","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.canlet.2018.05.009_bib56","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1073\/pnas.0611492104","article-title":"Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies","volume":"104","author":"Gerber","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.canlet.2018.05.009_bib57","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1073\/pnas.0931259100","article-title":"PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells","volume":"100","author":"Loke","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.canlet.2018.05.009_bib58","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3637","article-title":"Engagement of immune effector cells by trastuzumab induces HER2\/ERBB2 downregulation in cancer cells through STAT1 activation","volume":"16","author":"Shi","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2018.05.009_bib59","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1038\/onc.2011.42","article-title":"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs","volume":"30","author":"Weigelt","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2018.05.009_bib60","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1158\/1535-7163.MCT-09-1171","article-title":"Activated phosphoinositide 3-kinase\/AKT signaling confers resistance to trastuzumab but not lapatinib","volume":"9","author":"O'Brien","year":"2010","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2018.05.009_bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10549-007-9847-6","article-title":"Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells","volume":"112","author":"Zhang","year":"2008","journal-title":"Breast Canc. Res. Treat."},{"key":"10.1016\/j.canlet.2018.05.009_bib62","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/annonc\/mdp304","article-title":"Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines","volume":"21","author":"Kataoka","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2018.05.009_bib63","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2018.05.009_bib64","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-15-2001","article-title":"Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNgamma that induce PD-L1 expression in head and neck cancer","volume":"76","author":"Concha-Benavente","year":"2016","journal-title":"Cancer Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518303288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518303288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:39:34Z","timestamp":1759592374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383518303288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":64,"alternative-id":["S0304383518303288"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2018.05.009","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN\u03b3 secretion","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2018.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}